|
Apr 15
|
Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia
|
|
Apr 10
|
Tivic Health Systems, Inc. Regains Compliance with NASDAQ Minimum Bid Price Listing Rule
|
|
Mar 13
|
Tivic Health to Report 2024 Year-End Financial Results on March 21st Via Conference Call and Webcast
|
|
Feb 24
|
Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team
|
|
Feb 12
|
Tivic Health Acquires Exclusive Worldwide Rights to Phase III TLR5 Agonist from Statera Biopharma
|
|
Jul 23
|
Tivic Health Expands Intellectual Property Portfolio
|
|
Jun 18
|
Tivic Health: Christina Valauri Appointed to Board of Directors
|
|
May 9
|
Tivic Health Announces Pricing of $4.0 Million Public Offering
|
|
May 8
|
Tivic Health Announces Successful Completion of Non-Invasive Vagus Nerve Stimulation Study (VNS); Demonstrates Clinically Effective Biological Changes in the Autonomic, Cardiac, and Central Nervous Systems
|
|
Mar 25
|
Tivic Reports Fiscal Year 2023 Financial Results
|
|
Mar 19
|
Tivic Health to Report 2023 Year-End Financial Results on March 25th Via Conference Call and Webcast
|
|
Jul 17
|
Tivic Health Announces Pricing of $2.1 Million Public Offering of Common Stock
|
|
Jul 14
|
Tivic Health Announces Proposed Public Offering of Common Stock
|
|
Jul 11
|
Tivic Health Establishes Halal Compliance for ClearUP, FDA-Approved, Effective, Drug-Free Alternative for Sinus Pain, Pressure, and Congestion
|
|
May 1
|
Tivic Announces Appointment of New Interim CFO, Kimberly Bambach, and Strategic Advisor to the Board, Christine Valauri
|